Directory
>
Andy Holton
Andy Holton
Vice President of Market Access | Karyopharm Therapeutics Inc.
Lenexa, Kansas, United States
Andy Holton
Summary
Andy Holton is a seasoned executive in the biotechnology and pharmaceutical industry, currently serving as Vice President of Market Access at Karyopharm Therapeutics Inc. With a rich background in various therapeutic areas including oncology, cardiology, and infectious diseases, he excels in building market access strategies that drive business growth. His leadership style emphasizes team culture and strategic collaboration with C-suite partners, showcasing his strong interpersonal skills. Andy has a proven track record of launching innovative therapies and managing complex sales environments. He has held multiple senior roles at Karyopharm, demonstrating his commitment and expertise in the field. His educational foundation from The University of Kansas complements his extensive professional journey. Andy is not only a specialist in market access but also a visionary leader focused on shaping the future of healthcare through biotechnology.
Andy Holton
Work Experience
Vice President of Market Access at
Karyopharm Therapeutics Inc.
August 2023 - Present
Associate Vice President, Market Access at
Karyopharm Therapeutics Inc.
July 2022 - August 2023
Executive Director, US Market Access at
Karyopharm Therapeutics Inc.
July 2021 - August 2022
Senior Director, Strategic Accounts at
Karyopharm Therapeutics Inc.
May 2019 - June 2021
Corporate Account Director at
Karyopharm Therapeutics Inc.
December 2018 - May 2019
Regional Business Manager at
Puma Biotechnology, Inc.
July 2017 - December 2018
National Sales Director at
Cardiff Oncology
October 2015 - April 2017
Regional Business Director at
Amgen, Inc.
May 2012 - April 2014
Oncology District Sales Manager at
Sanofi
November 2004 - June 2012
Senior Analyst Marketing Research at
Sanofi
January 2002 - November 2004
Andy Holton
Education
January 1991 - January 1995
Bishop Ward High School
January 1987 - January 1991
Frequently Asked Questions about Andy Holton
What is Andy Holton email address?
Andy Holton's primary email address is ****@karyopharm.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Andy Holton work for?
Andy Holton is a Vice President of Market Access at Karyopharm Therapeutics Inc., a company specializing in Biological products, except diagnostic.
Where Andy Holton graduated from?
Andy Holton holds a degree in from University of Kansas.
How can I directly contact Andy Holton?
To contact Andy Holton directly, you can use the email address ****@karyopharm.com. Complete contact information is available upon registration with Muraena.
Who is Andy Holton?
Andy Holton is a seasoned executive in the biotechnology and pharmaceutical industry, currently serving as Vice President of Market Access at Karyopharm Therapeutics Inc. With a rich background in various therapeutic areas including oncology, cardiology, and infectious diseases, he excels in building market access strategies that drive business growth. His leadership style emphasizes team culture and strategic collaboration with C-suite partners, showcasing his strong interpersonal skills. Andy has a proven track record of launching innovative therapies and managing complex sales environments. He has held multiple senior roles at Karyopharm, demonstrating his commitment and expertise in the field. His educational foundation from The University of Kansas complements his extensive professional journey. Andy is not only a specialist in market access but also a visionary leader focused on shaping the future of healthcare through biotechnology.
Andy`s contact details
****@karyopharm.com
*******@trovagene.com
Colleagues
Vice President, Data Sciences
Independent Board Director
Lecturer, Graduate Program (Regulatory Affairs)
Vice President Research & Translational Medicine
Vice President, Business Operations and Corporate Affairs
Executive Director - Head of Medical Strategy Global Medical and Scientific Affairs
Vice President, Clinical Pharmacology
Vice President, Program Lead - Oncology
Vice President, Clinical Development - Myelofibrosis and MDS
Vice President, Regulatory Affairs